|
Market Closed -
Warsaw S.E.
18:55:50 25/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 210.50 PLN | +1.84% |
|
+0.86% | +36.76% |
| 08-25 | Bayer Group Receives Approval For Sevabertinib In Japan For HER2-Mutant Non-Small Cell Lung Cancer | CI |
| 08-24 | CAC 40 pauses ahead of Nvidia and Jackson Hole |  |
Company Valuation: Bayer AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 46,174 | 47,476 | 33,039 | 18,975 | 36,360 | 48,394 | - | - |
| Change | - | 2.82% | -30.41% | -42.57% | 91.62% | 33.1% | - | - |
| Enterprise Value (EV) 1 | 79,140 | 78,749 | 67,302 | 51,329 | 82,696 | 78,239 | 75,059 | 71,718 |
| Change | - | -0.49% | -14.54% | -23.73% | 61.11% | -5.39% | -4.06% | -4.45% |
| P/E | 46.1x | 11.5x | -11.2x | -7.43x | -10.1x | 21x | 15.8x | 13.7x |
| PBR | 1.4x | 1.22x | 1x | 0.59x | 1.4x | 1.72x | 1.56x | 1.43x |
| PEG | - | 0x | 0x | 0.6x | -0.2x | -0x | 0.5x | 0.9x |
| Capitalization / Revenue | 1.05x | 0.94x | 0.69x | 0.41x | 0.8x | 1.06x | 1.03x | 1x |
| EV / Revenue | 1.8x | 1.55x | 1.41x | 1.1x | 1.81x | 1.71x | 1.6x | 1.48x |
| EV / EBITDA | 7.08x | 5.83x | 5.75x | 5.07x | 8.55x | 8.08x | 7.29x | 6.48x |
| EV / EBIT | 10.8x | 8.51x | 8.87x | 9.44x | 16.2x | 13.6x | 11.6x | 10.1x |
| EV / FCF | 31.9x | 19x | 28.4x | 11.2x | 24x | -130x | 21x | 17.3x |
| FCF Yield | 3.13% | 5.26% | 3.52% | 8.94% | 4.16% | -0.77% | 4.77% | 5.79% |
| Dividend per Share 2 | 2 | 2.4 | 0.11 | 0.11 | 0.11 | 0.1569 | 0.53 | 0.9835 |
| Rate of return | 4.26% | 4.97% | 0.33% | 0.57% | 0.3% | 0.32% | 1.08% | 2% |
| EPS 2 | 1.02 | 4.22 | -2.99 | -2.6 | -3.68 | 2.342 | 3.12 | 3.606 |
| Distribution rate | 196% | 56.9% | -3.68% | -4.23% | -2.99% | 6.7% | 17% | 27.3% |
| Net sales 1 | 44,081 | 50,739 | 47,637 | 46,606 | 45,575 | 45,754 | 46,979 | 48,556 |
| EBITDA 1 | 11,179 | 13,513 | 11,706 | 10,123 | 9,669 | 9,684 | 10,295 | 11,072 |
| EBIT 1 | 7,295 | 9,257 | 7,589 | 5,436 | 5,108 | 5,735 | 6,474 | 7,076 |
| Net income 1 | 1,000 | 4,150 | -2,941 | -2,552 | -3,620 | 2,136 | 2,941 | 3,468 |
| Net Debt 1 | 32,966 | 31,273 | 34,263 | 32,354 | 46,336 | 29,845 | 26,665 | 23,323 |
| Reference price 2 | 47.00 | 48.32 | 33.63 | 19.31 | 37.01 | 49.26 | 49.26 | 49.26 |
| Nbr of stocks (in thousands) | 982,424 | 982,424 | 982,424 | 982,424 | 982,424 | 982,424 | - | - |
| Announcement Date | 3/1/22 A | 2/28/23 A | 3/5/24 A | 3/4/25 A | 3/4/26 A | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.12x | 12.73x | 25.81x | 0.56% | 1,100B | |
| 30.38x | - | - | 1.97% | 658B | |
| 33.92x | 7.84x | 16.3x | 2.58% | 470B | |
| 20.83x | 4.94x | 12.23x | 2.67% | 372B | |
| 22.71x | 5.84x | 14.47x | 2.73% | 304B | |
| 21.88x | 4.48x | 12.79x | 1.96% | 264B | |
| 27.97x | 7.21x | 12.8x | 2.28% | 239B | |
| 13.99x | 4.96x | 10.35x | 3.67% | 213B | |
| -45.46x | 6.56x | 25.6x | 2.22% | 184B | |
| Average | 17.93x | 6.82x | 16.29x | 2.29% | 422.54B | |
| Weighted average by Cap. | 25.31x | 8.41x | 18.55x | 1.89% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BAYN Stock
- BAY Stock
- Valuation Bayer AG
Select your edition
All financial news and data tailored to specific country editions
